Domainex, a biotechnology company, has secured further financing from existing shareholders Longbow Capital and The Capital Fund as well as new investor Takeda Research Investment. This funding will allow Domainex to advance its internal oncology drug research portfolio and take its novel cancer targets toward corporate collaborations and deals. CEO Eddy Littler welcomed the new investment and said it will help the company further develop its Combinatorial Domain Hunting technology and oncology pipeline over the next few months.